withaferin-a and Parkinsonian-Disorders

withaferin-a has been researched along with Parkinsonian-Disorders* in 2 studies

Other Studies

2 other study(ies) available for withaferin-a and Parkinsonian-Disorders

ArticleYear
Ashwagandha leaf extract: a potential agent in treating oxidative damage and physiological abnormalities seen in a mouse model of Parkinson's disease.
    Neuroscience letters, 2009, Apr-17, Volume: 454, Issue:1

    Parkinson's disease (PD) is a neurodegenerative disorder that leads to impairment of balance and coordination. Therapy for the disease is still under investigation. Withania somnifera (A-Extract), a herbal medicine, has been known for a spectrum of health-promoting effects including activation of immune, muscle and neuronal systems. Therefore effect of A-Extract in the mouse model of PD was examined. The midbrain and corpus striatum of PD mouse showed increased levels of superoxide dismutase, catalase and malondialdehyde; and reduced levels of glutathione and glutathione peroxidase compared to the control. Treatment with A-Extract 100mg/kg for 7 days significantly improved all these enzyme levels compared to A-Extract untreated PD mouse brain. In the PD mouse grooming, stride length, movement, rearing were found to be decreased compared to the control. In addition, narrow beam walk and foot slippery errors were increased. Treatment with A-Extract improved all these physiological abnormalities. These data suggests that A-Extract is a potential drug in treating oxidative damage and physiological abnormalities seen in the PD mouse, if documented also in patients with PD.

    Topics: Animals; Brain; Catalase; Female; Glutathione; Glutathione Peroxidase; Malondialdehyde; Mice; Motor Activity; Parkinsonian Disorders; Phytotherapy; Plant Extracts; Plant Leaves; Superoxide Dismutase; Withania

2009
Effect of BR-16A (Mentat), a polyherbal formulation on drug-induced catalepsy in mice.
    Indian journal of experimental biology, 2006, Volume: 44, Issue:1

    Parkinson's disease (PD) is a neurodegenerative disease characterized by the selective loss of dopamine (DA) neurons of the substantia nigra pars compacta (SNc). The events, which trigger and/or mediate the loss of nigral DA neurons, however, remain unclear. Neuroleptic-induced catalepsy has long been used as an animal model for screening drugs for Parkinsonism. Administration of haloperidol (1 mg/kg, ip) or reserpine (2 mg/kg, ip) significantly induced catalepsy in mice. BR-16A (50 and 100 mg/kg, po), a polyherbal formulation or ashwagandha (50 and 100 mg/kg, po), significantly reversed the haloperidol or reserpine-induced catalepsy. The results indicate that BR-16A or ashwagandha has protective effect against haloperidol or reserpine-induced catalepsy and provide hope that BR-16A could be used in preventing the drug-induced extrapyramidal side effects and may offer a new therapeutic approach to the treatment of Parkinson's disease.

    Topics: Animals; Catalepsy; Female; Haloperidol; Male; Medicine, Ayurvedic; Mice; Parkinsonian Disorders; Phytotherapy; Plant Extracts; Plants, Medicinal; Reserpine; Withania

2006